-
公开(公告)号：US10076562B2
公开(公告)日：2018-09-18
申请号：US15490261
申请日：2017-04-18
Inventor： Ashok K. Chopra , Vladimir L. Motin , Eric Rothe
CPC classification number: A61K39/0291 , A61K39/025 , A61K2039/53 , A61K2039/543 , A61K2039/545 , A61K2039/70 , C12N2710/10043 , Y02A50/407
Abstract: Provided herein are methods for using compositions that include a fusion protein having a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. In one embodiment the composition is used to confer immunity to plague, such as pneumonic plague, caused by Yersinia pestis. In one embodiment, the composition is administered to a mucosal surface, such as by an intranasal route. In one embodiment, the administration to a mucosal surface includes a vector that has a polynucleotide encoding a fusion protein, where the fusion protein includes a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. The administration is followed by a second administration by a different route, such as an intramuscular route. The second administration includes a fusion protein having the same three domains, and in one embodiment the fusion protein is the same one administered to a mucosal surface.
-
公开(公告)号：US10017563B2
公开(公告)日：2018-07-10
申请号：US15270461
申请日：2016-09-20
Inventor： Gerald B. Pier , Casie Anne Kelly-Quintos , Lisa Cavacini , Marshall R. Posner
IPC: A61K39/395 , C07K16/12 , A61K39/00
CPC classification number: C07K16/1271 , A61K2039/505 , C07K16/12 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , Y02A50/407
Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
-
3.发明授权
公开(公告)号：US09744199B2
公开(公告)日：2017-08-29
申请号：US14864098
申请日：2015-09-24
Applicant: ALMA MATER STUDIORUM—UNIVERSITA DI BOLOGNA
Inventor： Gabriella Campadelli , Laura Menotti
IPC: A61K35/00 , A61K35/76 , A61K49/04 , C07K14/005 , C12N7/00 , A61K39/245 , C07K14/035 , A61K35/763
CPC classification number: A61K35/763 , A61K49/04 , C07K14/005 , C07K2317/622 , C07K2319/33 , C07K2319/61 , C07K2319/74 , C12N7/00 , C12N2710/16621 , C12N2710/16622 , C12N2710/16632 , C12N2710/16633 , C12N2710/16651 , C12N2710/16722 , C12N2810/85 , Y02A50/407
Abstract: A modified Herpes Simplex Virus (HSV), which has a portion of gD (glycoprotein D) of the glycoproteic envelope deleted and a heterologous single chain antibody inserted in place of such deleted portion; the modified HSV is capable of infecting cells through receptor HER2/ErbB2 but not through receptors HVEM/HveA and nectin1/HveC; uses of the modified HSV and a process of the preparation thereof are also disclosed.
-
公开(公告)号：US09700615B2
公开(公告)日：2017-07-11
申请号：US14383995
申请日：2013-05-13
Applicant: Serum Institute of India Pvt. Ltd.
Inventor： Subhash V. Kapre
CPC classification number: A61K39/39 , A61K39/13 , A61K2039/55516 , C07K14/00 , C07K14/3156 , C12N7/00 , C12N2770/32634 , C12N2770/32671 , Y02A50/388 , Y02A50/407 , Y02A50/466 , Y02A50/469 , Y02A50/484
Abstract: The present invention is directed to methods for administering antigenic material to a patient as a vaccine against an infection comprising providing both an antigenic material specific to the desired immunological response desired plus an adjuvant comprised of a peptide of a sequence derived from the sequence of pneumococcal surface adhesin A protein (PsaA). Preferably the peptide comprises a sequences derived from one or more sequences of PsaA that contain the epitope regions or contiguous amino acids of SEQ ID NOs 1 or 2. The invention is also directed to vaccine compositions containing adjuvant of the invention and also adjuvant compositions of the invention.
-
公开(公告)号：US20160199475A1
公开(公告)日：2016-07-14
申请号：US14995743
申请日：2016-01-14
Applicant: Ashok K. Chopra , Jian Sha
Inventor： Ashok K. Chopra , Jian Sha
CPC classification number: A61K39/0291 , A61K45/06 , A61K2039/522 , A61K2039/572 , Y02A50/407
Abstract: Provided herein is a genetically modified Y. pestis that includes three alterations compared to a control Y. pestis. Two alterations include decreased mRNA, decreased protein, or a combination thereof, encoded by a lpp coding region and encoded by a msbB coding region. The third alteration is selected from an alteration of an intergenic region between the coding regions ypo1119 and ypo1120, and decreased mRNA, decreased protein, or a combination thereof, encoded by a coding region selected from pla, ypol717, ypmt1.80c, rbsA (ypo2500), ypo0498, vasK (ypo3603), ypo3164, hxuB (ypo3248), ypo1616, ypo1119, ypo1120, and ail. Also provided are compositions that include the genetically modified Y. pestis, and methods of using the genetically modified Y. pestis.
Abstract translation: 本文提供了一种遗传修饰的鼠疫耶氏酵母，其包括与对照鼠疫耶尔森氏菌相比的三个改变。 两个改变包括由lpp编码区编码并由msbB编码区编码的mRNA减少的mRNA，降低的蛋白质或其组合。 第三改变选自编码区ypo1119和ypo1120之间的基因间区域的改变，以及由选自pla，ypol717，ypmt1.80c，rbsA（ypo2500）的编码区编码的mRNA，降低的蛋白质或其组合的减少 ），ypo0498，vasK（ypo3603），ypo3164，hxuB（ypo3248），ypo1616，ypo1119，ypo1120和ail。 还提供了包括遗传修饰的鼠疫耶氏菌的组合物，以及使用遗传修饰的鼠疫耶氏菌的方法。
-
公开(公告)号：US20160075782A1
公开(公告)日：2016-03-17
申请号：US14807522
申请日：2015-07-23
Applicant: E.R. Squibb & Sons, L. L. C.
Inventor： Alan J. Korman , Mark J. Selby , Changyu Wang , Mohan Srinivasan , David B. Passmore , Haichun Huang , Haibin Chen
IPC: C07K16/28
CPC classification number: C07K16/2827 , A61K45/06 , A61K47/6817 , A61K47/6825 , A61K47/6849 , A61K2039/505 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K2317/21 , C07K2317/41 , C07K2317/56 , C07K2317/567 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/77 , C07K2317/92 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/41 , Y02A50/412 , Y02A50/466
Abstract: The present disclosure provides isolated monoclonal antibodies particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.
Abstract translation: 本公开提供分离的单克隆抗体，特别是以高亲和力特异性结合PD-L1的人单克隆抗体。 还提供了编码本公开的抗体的核酸分子，表达载体，宿主细胞和用于表达本公开的抗体的方法。 还提供了免疫偶联物，双特异性分子和包含本发明抗体的药物组合物。 本公开还提供了使用抗PD-L1抗体检测PD-L1的方法以及用于治疗各种疾病（包括癌症和感染性疾病）的方法。
-
公开(公告)号：US20150308988A1
公开(公告)日：2015-10-29
申请号：US14705713
申请日：2015-07-14
Applicant: XOMA TECHNOLOGY LTD.
Inventor： Susan Joyce Babuka , Chin-Yi Huang , Mingxiang Li
CPC classification number: G01N30/36 , A61K39/39591 , A61K2039/507 , C07K16/1282 , G01N25/20 , Y02A50/386 , Y02A50/388 , Y02A50/394 , Y02A50/401 , Y02A50/407 , Y02A50/41 , Y02A50/412 , Y02A50/423 , Y02A50/466 , Y02A50/469
Abstract: This invention relates to stable formulations of multiple antibodies comprising a plurality of antibodies and an effective amount of a succinate buffer wherein the pH of the formulation is between about 4.5 and about 7.0.
Abstract translation: 本发明涉及包含多种抗体和有效量的琥珀酸盐缓冲液的多种抗体的稳定制剂，其中制剂的pH为约4.5至约7.0。
-
公开(公告)号：US20150147344A1
公开(公告)日：2015-05-28
申请号：US14550429
申请日：2014-11-21
Applicant: Universite d'Aix Marseille , INSERM (Institut National de la Sante et de la Recherche Medicale)
Inventor： Daniel Olive
IPC: C07K16/28 , A61K39/395
CPC classification number: C07K16/2818 , A61K39/3955 , A61K2039/505 , C07K16/2827 , C07K16/2878 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/74 , Y02A50/386 , Y02A50/388 , Y02A50/407 , Y02A50/41 , Y02A50/412 , Y02A50/466 , Y02A50/484
Abstract: The invention relates to BTLA antibodies that block BTLA-HVEM interaction and uses thereof.
Abstract translation: 本发明涉及阻断BTLA-HVEM相互作用的BTLA抗体及其用途。
-
9.发明授权Compositions, methods and uses for expression of enterobacterium-associated peptides 有权用于表达肠杆菌相关肽的组合物，方法和用途
公开(公告)号：US09028809B2
公开(公告)日：2015-05-12
申请号：US13511652
申请日：2010-11-24
Applicant: Dan T. Stinchcomb , Jorge E. Osorio , Timothy D. Powell , Joseph N. Brewoo
Inventor： Dan T. Stinchcomb , Jorge E. Osorio , Timothy D. Powell , Joseph N. Brewoo
IPC: A01N63/00 , A61K39/275 , A61K39/00 , A61K39/02
CPC classification number: A61K39/025 , A61K39/0291 , A61K2039/5256 , A61K2039/53 , C07K14/24 , C12N7/00 , C12N15/86 , C12N2710/24134 , C12N2710/24141 , C12N2710/24143 , C12N2710/24171 , C12N2840/002 , C12N2840/85 , Y02A50/407
Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing enterobacterial-associated peptides. In some embodiments, enterobacterial-associated peptides include, but are not limited to plague-associated peptides. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, attenuated or modified vaccinia virus vectors expressing enterobacterial-associated peptides. In other embodiments, vaccine compositions are reported of use in a subject.
Abstract translation: 本发明的实施方案通常公开了用于产生和表达肠细菌相关肽的方法，组合物和用途。 在一些实施方案中，肠细菌相关肽包括但不限于瘟疫相关肽。 在某些实施方案中，方法通常涉及制备和使用构建体的组合物，包括但不限于表达肠细菌相关肽的减毒或修饰的痘苗病毒载体。 在其它实施方案中，报告了在受试者中使用的疫苗组合物。
-
公开(公告)号：US20140328880A1
公开(公告)日：2014-11-06
申请号：US14306815
申请日：2014-06-17
Applicant: University of Massachusetts
Inventor： Egil Lien , Jon D. Goguen
IPC: A61K39/02 , A61K39/118
CPC classification number: A61K39/0291 , A61K39/0208 , A61K39/025 , A61K39/098 , A61K39/118 , A61K2039/55572 , C12Q1/025 , G01N33/56911 , Y02A50/407 , Y02A50/478
Abstract: Described herein are microorganisms that are modified so that they have an increased ability to be recognized by the innate immune system of a eukaryote, relative to an unmodified microorganism. A microorganism may be a gram-negative bacterium that has been modified to produce high potency lipopolysaccharide, e.g., Yersinia pestis expressing LpxL. Such modified microorganisms may be used as vaccines for protection against an infection by the unmodified microorganism. They may also be used as delivery vehicles of one or more heterologous antigens, e.g., antigens from pathogens or those associated with a hyperproliferative eukaryotic cell.
Abstract translation: 这里描述的是相对于未修饰的微生物进行修饰以使得它们具有增强的真核生物免疫系统识别能力的微生物。 微生物可以是已被修饰以产生高效力脂多糖的革兰氏阴性细菌，例如表达LpxL的耶尔森氏菌。 这种修饰的微生物可以用作防止未经修饰的微生物感染的疫苗。 它们还可以用作一种或多种异源抗原的递送载体，例如来自病原体的抗原或与过度增殖的真核细胞相关的抗原。
